{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319032116992.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1097/tp.0b013e3182419864"}},{"identifier":{"@type":"URI","@value":"http://journals.lww.com/00007890-201202270-00013"}}],"dc:title":[{"@value":"Allosensitization Rate of Male Patients Awaiting First Kidney Grafts After Leuko-Depleted Blood Transfusion"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319032116992","@type":"Researcher","foaf:name":[{"@value":"Gowrie S. Balasubramaniam"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319032116995","@type":"Researcher","foaf:name":[{"@value":"Matthew Morris"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319032116993","@type":"Researcher","foaf:name":[{"@value":"Arun Gupta"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319032116994","@type":"Researcher","foaf:name":[{"@value":"Irene Rebello Mesa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319032116996","@type":"Researcher","foaf:name":[{"@value":"Raj Thuraisingham"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319032116997","@type":"Researcher","foaf:name":[{"@value":"Neil Ashman"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00411337"}],"prism:publicationName":[{"@value":"Transplantation"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2012-02-27","prism:volume":"93","prism:number":"4","prism:startingPage":"418","prism:endingPage":"422"},"reviewed":"false","url":[{"@id":"http://journals.lww.com/00007890-201202270-00013"}],"createdAt":"2012-01-07","modifiedAt":"2024-04-17","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390001204679702528","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"第7章 赤血球輸血"},{"@value":"第7章 赤血球輸血"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282763084926208","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"科学的根拠に基づいた赤血球製剤の使用ガイドライン（改訂第2版）"},{"@language":"en","@value":"GUIDELINE FOR THE USE OF RED BLOOD CELL PRODUCTS BASED ON SCIENTIFIC EVIDENCE (REVISION 2ND EDITION)"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1097/tp.0b013e3182419864"},{"@type":"CROSSREF","@value":"10.3925/jjtc.64.688_references_DOI_2yV2kDxOIMmvdvBfu0DE7ihjgOj"},{"@type":"CROSSREF","@value":"10.4009/jsdt.49.145_references_DOI_2yV2kDxOIMmvdvBfu0DE7ihjgOj"}]}